🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchPemvidutide vs survodutide — GCG/GLP-1 dual agonist head-to-head? Page 2

Pemvidutide vs survodutide — GCG/GLP-1 dual agonist head-to-head?

MASHdoc_SA Wed, May 27, 2026 at 3:24 AM 8 replies 369 viewsPage 2 of 2
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
May 27, 2026 at 6:48 PM#6
Dr.BariatricHTX said:
Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.

I read this differently from Dr.BariatricHTX, on substance rather than tone. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.

11 14julia.endo, JessicaM_2024, TomFromTexas and 8 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
May 28, 2026 at 12:55 AM#7

Adding the numbers, since they settle part of this. Practical numbers: half-life about 5 days, steady state 3 to 4 weeks, ladder 2.5 / 5 / 7.5 / 10 / 12.5 / 15mg, and the maintenance doses with published data behind them are 5, 10 and 15mg.

12 15tommy_boulder, hyun_seoul, jim_asheville and 9 others
Reply Quote Save Share Report
chris_chi24
Member
389
1,678
Sep 2024
Chicago, IL
May 28, 2026 at 7:02 AM#8
Dr.KarenChen said:
The "tirzepatide is simply better" summary irritates me.

Adding the part of the answer the thread has not reached. SURMOUNT-1 landed around 20.9% mean weight loss at 15mg over 72 weeks, against roughly 15% for semaglutide 2.4mg in STEP 1. Different trials, different populations, so the comparison is indicative rather than decisive — but SURPASS-2 was a genuine head-to-head and it pointed the same way.

13 16MaxMetOK, MounjBrad, nick_newbie and 10 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
tane_welly
Member
234
1,123
Sep 2024
Wellington, NZ
May 28, 2026 at 1:09 PM#9

One thing that is still open after hans_munich’s answer:

Whether anyone has held 10mg long term rather than climbing, and what happened over the following year?

14 17marco_milano, pam_columbus, nick_SD_fit and 11 others
Reply Quote Save Share Report
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
May 29, 2026 at 6:30 PM#10

OP back with an update, since a thread like this is useless without one.

Reporting back after another eight months at the same dose. Still losing slowly, no new side effects, and no reason I can find to climb further.

28 3kate.chem, DataDave, Dr.GutHealth and 25 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register